Shigellosis pathophysiology

Revision as of 21:19, 5 April 2015 by YazanDaaboul (talk | contribs)
Jump to navigation Jump to search

Shigellosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Classification

Causes

Differentiating Shigellosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Shigellosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Shigellosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Shigellosis pathophysiology

CDC on Shigellosis pathophysiology

Shigellosis pathophysiology in the news

Blogs on Shigellosis pathophysiology

Directions to Hospitals Treating Shigellosis

Risk calculators and risk factors for Shigellosis pathophysiology

Overview

Pathophysiology

Shigella infection is typically via ingestion (fecal–oral contamination); depending on age and condition of the host as few as ten bacterial cells can be enough to cause an infection. Shigella cause dysentery that results in the destruction of the epithelial cells of the intestinal mucosa in the cecum and rectum. Some strains produce enterotoxin and Shiga toxin, similar to the verotoxin of E. coli O157:H7.[1] Both Shiga toxin and verotoxin are associated with causing hemolytic uremic syndrome.

Shigella invade the host through epithelial cells of the small intestine. Using a Type III secretion system acting as a biological syringe, the bacterium injects Ipa protein into cell, triggering bacterial invasion, and the subsequently lysis of vacuolar membranes. It utilizes a mechanism for its motility by which its IcsA triggers actin polymerization in the host cell in a "rocket" propulsion fashion for cell-to-cell spread.

The most common symptoms are diarrhea, fever, nausea, vomiting, stomach cramps, and straining to have a bowel movement. The stool may contain blood, mucus, or pus (e.g. dysentery). In rare cases, young children may have seizures. Symptoms can take as long as a week to show up, but most often begin two to four days after ingestion. Symptoms usually last for several days, but can last for weeks. Shigella is implicated as one of the pathogenic causes of reactive arthritis worldwide.[2]

Severe dysentery can be treated with ampicillin, TMP-SMX, or fluoroquinolones such as ciprofloxacin.

Histopathology of Shigellosis (Bacillary Dysentery)

{{#ev:youtube|1D1m4rybDrc}}

References

  1. Hale TL, Keusch GT (1996). Shigella. in: Baron's Medical Microbiology (Baron S et al, eds.) (4th ed. ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1.
  2. Hill Gaston JS, Lillicrap MS (2003). "Arthritis associated with enteric infection". Best practice & research. Clinical rheumatology. 17 (2): 219–39. PMID 12787523.


Template:WikiDoc Sources